An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder

Annabeth P. Groenman*, Lizanne J. S. Schweren, Andrea Dietrich, Pieter J. Hoekstra

*Corresponding author voor dit werk

Onderzoeksoutputpeer review

31 Citaten (Scopus)
393 Downloads (Pure)

Samenvatting

Introduction: Methylphenidate is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). Although methylphenidate has a well-established evidence base for treating ADHD, its long-term benefits are unclear.Areas covered: Physical adverse effects, psychiatric adverse events and brain developmentExpert opinion: Some physical adverse events have been described (e.g. sleep disturbances, growth reduction, loss of appetite), although most are of transient nature. Psychiatric adverse events seem more related to the diagnosis ADHD itself, and not stimulant treatment. Concluding, short-to-mid-term use (i.e., up to 2years) stimulants are relatively safe, but much less is known about longer-term efficacy and safety of these drugs.

Originele taal-2English
Pagina's (van-tot)455-464
Aantal pagina's10
TijdschriftExpert Opinion on Drug Safety
Volume16
Nummer van het tijdschrift4
DOI's
StatusPublished - apr.-2017

Vingerafdruk

Duik in de onderzoeksthema's van 'An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder'. Samen vormen ze een unieke vingerafdruk.

Citeer dit